HIGH-ACTIVITY I-125 INTERSTITIAL IRRADIATION IN THE TREATMENT OF PEDIATRIC CENTRAL-NERVOUS-SYSTEM TUMORS - A PILOT-STUDY

被引:4
|
作者
FONTANESI, J
HEIDEMAN, RL
MUHLBAUER, M
MULHERN, R
SANFORD, RA
DOUGLASS, EC
KOVNAR, E
OCHS, JJ
KUTTESCH, JF
TAI, D
KUN, LE
机构
[1] ST JUDE CHILDRENS RES HOSP, DEPT RADIAT ONCOL, MEMPHIS, TN 38105 USA
[2] ST JUDE CHILDRENS RES HOSP, DEPT HEMATOL ONCOL, MEMPHIS, TN 38105 USA
[3] ST JUDE CHILDRENS RES HOSP, DEPT NEUROL, MEMPHIS, TN 38105 USA
[4] ST JUDE CHILDRENS RES HOSP, DIV BEHAV MED, MEMPHIS, TN 38105 USA
[5] UNIV TENNESSEE, COLL MED, DEPT RADIOL, MEMPHIS, TN USA
[6] UNIV TENNESSEE, COLL MED, DEPT NEUROSURG, MEMPHIS, TN USA
[7] UNIV TENNESSEE, COLL MED, DEPT PEDIAT, MEMPHIS, TN USA
[8] ST CHRISTOPHERS HOSP CHILDREN, PHILADELPHIA, PA 19133 USA
关键词
I-125; BRAIN TUMORS; INTERSTITIAL IMPLANTS; PEDIATRIC TUMORS;
D O I
10.1159/000120918
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Malignant pediatric tumors of the central nervous system (CNS) have a poor prognosis, with local failure rates as high as 50%, In an attempt to improve local tumor control, we used stereotactic interstitial therapy with I-125 implants in patients with recurrent/secondary or newly diagnosed CNS malignancies, Catheters were placed using computed tomography (CT) guidance; computerized dosimetry was completed with the aid of orthogonal films. Implants delivered 1,000 cGy/day to the tumor periphery (0.5 cm beyond the boundary of enhancement on CT scans), to a total dose of 60 Gy, Hyperfractionated external beam irradiation (HEBI), started 2-4 weeks after removal of implants, delivered total doses of 66-70.4 Gy in 110-cGy fractions twice daily to a 3-cm margin around the implant volume, Eight of the 1 1 patients with newly diagnosed tumors also received 48.4 Gy HEBI to the craniospinal axis. Tumor regression was noted at 2 months after implantation in the 4 patients treated for recurrent/secondary tumors; local progression was subsequently documented in 2 cases at 6 and 20 months after implantation, while a third patient died 6 months after implantation with no evidence of local recurrence. The remaining recurrent/secondary tumor patient has no evidence of active recurrence 15 months after implantation. Local control was maintained in 9 of the 1 1 patients treated for primary tumors for a median of 27 months (range 15 to 48+ months). The two local failures occurred at 5 and 7 months after implantation. Six patients are alive without evidence of progressive disease (median = 23 months after implantation), There were no severe acute toxicities, but 7 patients later developed histologically confirmed tumor necrosis, Quality of life assessment (QLA) following initial primary therapy with implantation was evaluated utilizing an established criteria and found to be excellent with only one child showing marked QLA score decrease which was related to neurosurgical intervention for radiation-induced necrosis and dysfunctional family social situation, This small series suggests that stereotactic I-125 implantation followed by HEBI merits further evaluation in selected children with supratentorial malignant lesions.
引用
收藏
页码:289 / 297
页数:9
相关论文
共 50 条
  • [41] Pilot study of systemic and intrathecal mafosfamide followed by conformal radiation for infants with intracranial central nervous system tumors: a pediatric brain tumor consortium study (PBTC-001)
    Susan M. Blaney
    Mehmet Kocak
    Amar Gajjar
    Murali Chintagumpala
    Thomas Merchant
    Mark Kieran
    Ian F. Pollack
    Sri Gururangan
    Russ Geyer
    Peter Phillips
    Roger E. McLendon
    Roger Packer
    Stewart Goldman
    Anu Banerjee
    Richard Heideman
    James M. Boyett
    Larry Kun
    Journal of Neuro-Oncology, 2012, 109 : 565 - 571
  • [42] A phase I trial of pomalidomide for children with recurrent, progressive/refractory central nervous system (CNS) tumors: A Pediatric Brain Tumor Consortium (PBTC) study.
    Fangusaro, Jason R.
    Mitchell, Duane Anthony
    Kocak, Mehmet
    Onar-Thomas, Arzu
    Sadighi, Zsila Sousan
    Baxter, Patricia Ann
    Hwang, Eugene I.
    Huang, Jianping
    Dunkel, Ira J.
    Fouladi, Maryam
    Warren, Katherine E.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [43] Pediatric Phase I Trial and Pharmacokinetic Study of Trebananib in Relapsed Solid Tumors, Including Primary Tumors of the Central Nervous System ADVL1115: A Children's Oncology Group Phase I Consortium Report
    Leary, Sarah E. S.
    Park, Julie R.
    Reid, Joel M.
    Ralya, Andrew T.
    Baruchel, Sylvain
    Wu, Bing
    Roberts, Timothy P. L.
    Liu, Xiaowei
    Minard, Charles G.
    Fox, Elizabeth
    Weigel, Brenda
    Blaney, Susan
    CLINICAL CANCER RESEARCH, 2017, 23 (20) : 6062 - 6069
  • [44] Phase I Study of SU5416, a Small Molecule Inhibitor of the Vascular Endothelial Growth Factor Receptor (VEGFR) in Refractory Pediatric Central Nervous System Tumors
    Kieran, Mark W.
    Supko, Jeffrey G.
    Wallace, Dana
    Fruscio, Robert
    Poussaint, Tina Young
    Phillips, Peter
    Pollack, Ian
    Packer, Roger
    Boyett, James M.
    Blaney, Susan
    Banerjee, Anu
    Geyer, Russ
    Friedman, Henry
    Goldman, Stewart
    Kun, Larry E.
    MacDonald, Tobey
    PEDIATRIC BLOOD & CANCER, 2009, 52 (02) : 169 - 176
  • [45] THE ANTIDEMENTIC PANTOYL-GABA ENHANCES HIGH-AFFINITY CHOLINE UPTAKE BY SHORT-TERM AND CHAT ACTIVITY BY LONG-TERM TREATMENT IN THE CENTRAL-NERVOUS-SYSTEM
    NAKAHIRO, M
    FUKUCHI, I
    YOSHIDA, H
    NEUROCHEMICAL RESEARCH, 1986, 11 (01) : 118 - 118
  • [46] A phase I study of cetuximab and irinotecan in pediatric patients with refractory central nervous system (CNS) tumors: A preliminary safety and efficacy report from the pediatric oncology experimental therapeutics investigators' consortium (poetic)
    Gore, Lia
    Kuttesch, John
    Herzog, Cynthia
    Bagatell, Rochelle
    Boklan, Jessica
    Arceci, Robert
    Katzenstein, Howard
    Whitlock, James
    Deshpande, Rashmi
    Lu, Haolan
    Weber, Martin
    Trippett, Tanya
    NEURO-ONCOLOGY, 2008, 10 (03) : 506 - 506
  • [47] Phase I and pharmacokinetic study of the oral farnesyltransferase inhibitor lonafarnib administered twice daily to pediatric patients with advanced central nervous system tumors using a modified continuous reassessment method: A Pediatric Brain Tumor Consortium Study
    Kieran, Mark W.
    Packer, Roger J.
    Onar, Arzu
    Blaney, Susan M.
    Phillips, Peter
    Pollack, Ian F.
    Geyer, J. Russell
    Gururangan, Sri
    Banerjee, Anu
    Goldman, Stewart
    Turner, Christopher D.
    Belasco, Jean B.
    Broniscer, Alberto
    Zhu, Yali
    Frank, Emily
    Kirschmeier, Paul
    Statkevich, Paul
    Yver, Antoine
    Boyett, James M.
    Kun, Larry E.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (21) : 3137 - 3143
  • [48] Memantine to Reduce Cognitive Impairment After Radiation in Children: A Pilot Study Evaluating the Feasibility of Memantine in Reducing Cognitive Impairment in Pediatric Patients after Radiation Therapy for Central Nervous System Tumors
    Mckone, Elizabeth L.
    Breen, William G.
    Foster, Nathan R.
    Bogan, Aaron W.
    Connors, Margaret A.
    Alstat, Reece A.
    Schwartz, Jonathan D.
    Mahajan, Anita
    Ahmed, Safia K.
    Laack, Nadia N.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2024, 120 (04): : 1032 - 1038
  • [49] A Case Series of Children With Medulloblastoma Depicting the Disparities in Care and the Challenges in the Detection and Treatment of Pediatric Central Nervous System Tumors in Low-Resource Settings: A Case Study of Uganda
    Mwebe, Victoria Katasi
    Wegoye, Emmanuel
    Ssekabunga, Julie
    Onen, Justine
    Kibudde, Solomon
    Chintagumpala, Murali
    Lubega, Joseph
    PEDIATRIC NEUROLOGY, 2024, 161 : 67 - 72
  • [50] A phase II prospective study of sequential myeloablative chemotherapy with hematopoietic stem cell rescue for the treatment of selected high risk and recurrent central nervous system tumors
    Rosenfeld, Amy
    Kletzel, Morris
    Duerst, Reggie
    Jacobsohn, David
    Haut, Paul
    Weinstein, Joanna
    Rademaker, Alfred
    Schaefer, Colleen
    Evans, Lauren
    Fouts, Molly
    Goldman, Stewart
    JOURNAL OF NEURO-ONCOLOGY, 2010, 97 (02) : 247 - 255